Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Amid the worst U.S.-China trade clash in modern history, Michelle Xia thinks she has something Chinese that Americans will want. It isn’t a $3 T-shirt or an electronic gadget. It is a cancer drug her ...